Allosteric inhibition of the hepatitis C virus NS5B polymerase: In silico strategies for drug discovery and development

Future Medicinal Chemistry

Volumn 3, Issue 8, 2011, Pages 1027-1055

  Barreca, Maria Letizia ^a   Iraci, Nunzio ^a   Manfroni, Giuseppe ^a   Cecchetti, Violetta ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; ACRYLIC ACID; ANTHRANILIC ACID; BENZOFURAN DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; FILIBUVIR; INDOLE DERIVATIVE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5B; PHENYLALANINE; PYRAZOLOPYRIMIDINE DERIVATIVE; QUINOLONE DERIVATIVE; QUINOXALINE; RHODANINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TEGOBUVIR; THIOCARBAMIC ACID; THIOPHENE DERIVATIVE; THIOURACIL;

ALLOSTERISM; COMPUTER MODEL; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IC 50; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; VIRUS INHIBITION;

ALLOSTERIC REGULATION; ANTIVIRAL AGENTS; COMPUTER-AIDED DESIGN; DRUG DISCOVERY; HEPACIVIRUS; HEPATITIS C; HUMANS; MODELS, MOLECULAR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79959802300     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.53     Document Type: Review

References (139)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 29(1), 74-81 (2009
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902), 359-362 (1989 (Pubitemid 19117877)
3. Robertson B, Myers G, Howard C et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol. 143(12), 2493-2503 (1998 (Pubitemid 29022697)
4. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 39(1), 5-19 (2004 (Pubitemid 38461460)
5. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment. Pharm. Ther. 32(1), 14-28 (2010
6. Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J. Gastroenterol. 13(43), 5673-5681 (2007 (Pubitemid 350120218)
7. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-CJ. Viral Hepatitis. 16(6), 377-387 (2009
8. Schinazi RF, Coats SJ, Bassit LC, Lennerstrand J, Nettles JH, Hurwitz SJ. Approaches for the development of antiviral compounds: the case of hepatitis C virus. In: Handbook of Experimental Pharmacology (Volume 189Krausslich H-G, Bartenschlager R (EdsSpringer-Verlag, Berlin, Germany 25-51 (2009
9. Flisiak R, Parfieniuk A. Investigational drugs for hepatitis C. Expert Opin. Investi. Drugs. 19(1), 63-75 (2010
10. Deore RR, Chern JW. NS5B RNA dependent RNA polymerase inhibitors: the promising approach to treat hepatitis C virus infections. Curr. Med. Chem. 17(32), 3806-3826 (2010
11. Legrand-Abravanel F, Nicot F, Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin. Inv. Drugs 19(8), 963-975 (2010
12. Li H, Shi ST. Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges. Future Med. Chem. 2(1), 121-141 (2010
13. Watkins WJ, Ray AS, Chong LS. HCV NS5B polymerase inhibitors. Curr. Opin. Drug Discov. Devel. 13(4), 441-465 (2010
14. Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin. Inv. Drugs 18(6), 709-725 (2009
15. Talele TT. Multiple allosteric pockets of HCV NS5B polymerase and its inhibition: a structure-based insight. Curr. Bioact. Compd 4, 96-109 (2008
16. Vliegen I, Paeshuyse J, Marbery E et al. GS-9190, a novel substituted imidazo-pyridine analogue, is a potent inhibitor of hepatitis C virus replication in vitro and remains active against known drug resistant mutants. Hepatology 46(4, Suppl. 1), 855A (2007
17. Shih IH, Vliegen I, Peng B et al. Mechanistic characterization of GS-9190, a novel non-nucleoside inhibitor of HCVNS5B polymerase with potent antiviral activity and a unique mechanism of action. Hepatology 46(4, Suppl. 1), 859A (2007
18. Parkinson T, Pryde DC. Small molecule drug discovery for dengue and West Nile viruses: applying experience from hepatitis C virus. Future Med. Chem. 2(7), 1181-1203 (2010
19. Bavisotto L, Wang CC, Jacobson IM et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCVNS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology 46(4, Suppl. 1), 255A (2007
20. Li H, Tatlock J, Linton A et al. Discovery of (R)-6-cyclopentyl-6-(2-(2, 6-diethylpyridin- 4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4] triazolo[1,5-a]pyrimidin- 2-yl)methyl)-4- hydroxy-5,6-dihydropyran-2-on e (PF- 00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J. Med. Chem. 52(5), 1255-1258 (2009
21. Berman HM, Westbrook J, Feng Z et al. The Protein Data Bank. Nucleic Acids Res. 28(1), 235-242 (2000). (Pubitemid 30047768)
22. Rester U. From virtuality to reality - virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr. Opin. Drug Discov. Devel. 11(4), 559-568 (2008 (Pubitemid 351950850)
23. Talele TT, Khedkar SA, Rigby AC. Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr. Top. Med. Chem. 10(1), 127-141 (2010
24. Young DC. Computational Drug Design: A Guide for Computational and Medicinal Chemists. John Wiley & Sons, Inc., NY, USA (2009
25. Liao CZ, Nicklaus MC. Computer tools in the discovery of HIV-1 integrase inhibitors. Future Med. Chem. 2(7), 1123-1140 (2010
26. Zonta N, Coluccia A, Brancale A. Advanced in silico approaches in antiviral research. Antivir. Chem. Chemother. 20(4), 147-151 (2010
27. Congreve M, Murray CW, Blundell TL. Keynote review: structural biology and drug discovery. Drug Discov. Today 10(13), 895-907 (2005 (Pubitemid 40922788)
28. Skjevik AA, Teigen K, Martinez A. Overview of computational methods employed in early-stage drug discovery. Future Med. Chem. 1(1), 49-63 (2009
29. Todeschini R, Consonni V. Handbook of Molecular Descriptors. Mannhold R, Kubini H, Folkers G (EdsWiley-VCH, Weinheim, Germany (2000
30. Todeschini R, Consonni V. Molecular descriptors for chemoinformatics. In: Methods and Principles in Medicinal Chemistry (Volume 41Mannhold R, Kubinyi H, Timmerman H (EdsWiley-VCH, Weinheim, Germany (2009
31. Roy K. On some aspects of validation of predictive quantitative structure-activity relationship models. Expert Opin. Drug Discov. 2 (12), 1567-1577 (2007 (Pubitemid 350285346)
32. Wold S, Eriksson L, Clementi S, Tahri A. Statistical validation of QSAR results. In: Chemometric Methods in Molecular Design. van de Waterbeemd H (Ed.Wiley-VCH, Weinheim, Germany (2008
33. Mammone A, Turchi M, Cristianini N. Support vector machines. Wiley Inter. Reviews: Comput. Statistics 1(3), 283-289 (2009
34. Vapnik V. Statistical Learning Theory. Wiley-Interscience, NY, USA (1998
35. Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comp. Sci. 34(4), 854-866 (1994
36. Cramer RD, Bunce JD, Patterson DE, Frank IE. Cross-validation, bootstrapping, and partial least-squares compared with multiple-regression in conventional QSAR studies. Quant. Struct. Act. Relation. 7(1), 18-25 (1988
37. Cramer RD, Patterson DE, Bunce JD. Comparative molecular-field analysis (CoMFA) 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110(18), 5959-5967 (1988
38. Klebe G, Abraham U, Mietzner T. Molecular similarity indexes in a comparative-analysis (CoMSIA) of drug molecules to correlate and predict their biological-activity. J. Med. Chem. 37(24), 4130-4146 (1994 (Pubitemid 24379702)
39. Wold S, Sjostrom M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemometr. Intell. Lab. 58(2), 109-130 (2001 (Pubitemid 33033283)
40. Baroni M, Costantino G, Cruciani G, Riganelli D, Valigi R, Clementi S. Generating optimal linear PLS estimations (GOLPE) - an advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct. Act. Relation. 12(1), 9-20 (1993 (Pubitemid 23128716)
41. Cruciani G, Watson KA. Comparative molecular-field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen-phosphorylase-B. J. Med. Chem. 37(16), 2589-2601 (1994 (Pubitemid 24276786)
42. Goodford PJ. A Computational-procedure for determining energetically favorable binding-sites on biologically important macromolecules. J. Med. Chem. 28(7), 849-857 (1985 (Pubitemid 15012490)
43. Leardi R, Gonzalez AL. Genetic algorithms applied to feature selection in PLS regression: how and when to use them. Chemometr. Intell. Lab. 41(2), 195-207 (1998 (Pubitemid 28348346)
44. Tropsha A, Zheng W, Ethiraj G. Quick and dirty? No, fast and accurate: the K nearest neighbor QSAR method. Presented at: 217th American Chemical Society Meeting. Anaheim, CA, USA, 21-25 March 1999.
45. Zheng WF, Tropsha A. A novel nonlinear QSAR method based on K-nearest neighbor principle and variable selection. Presented at: 215th American Chemical Society Meeting. Dallas, TX, USA, 29 March-2 April 1998.
46. Lengauer T, Rarey M. Computational methods for biomolecular docking. Curr. Opin. Struct. Biol. 6(3), 402-406 (1996 (Pubitemid 26197442)
47. Oda A, Tsuchida K, Takakura T, Yamaotsu N, Hirono S. Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes. J. Chem. Inf. Model. 46(1), 380-391 (2006 (Pubitemid 43282129)
48. Sotriffer CA. Accounting for induced-fit effects in docking: what is possible and what is not? Curr. Top. Med. Chem. 11, 179-191 (2011
49. Barreca ML, Iraci N, De Luca L, Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem 4(9), 1446-1456 (2009
50. Moitessier N, Englebienne P, Lee D, Lawandi J, Corbeil CR. Towards the development of universal, fast and highly accurate docking/ scoring methods: a long way to go. Brit. J. Pharmacol. 153(Suppl. 1), S7-S26 (2008 (Pubitemid 351340987)
51. Tuccinardi T. Docking-based virtual screening: recent developments. Comb. Chem. High Throughput Screen. 12(3), 303-314 (2009
52. Gao Q, Yang L, Zhu Y. Pharmacophore based drug design approach as a practical process in drug discovery. Curr. Comput. Aided Drug Des. 6(1), 37-49 (2010
53. Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov. Today 15(11-12), 444-450 (2010
54. Sun H. Pharmacophore-based virtual screening. Curr. Med. Chem. 15(10), 1018-1024 (2008 (Pubitemid 351736404)
55. Kyun-Hwan K, Nam Doo K, Seong BL. Pharmacophore-based virtual screening: a review of recent applications. Expert Opin. Drug Discov. 5(3), 205-222 (2010
56. Barreca ML, Rao A, De Luca L et al. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem. 48(9), 3433-3437 (2005 (Pubitemid 40628061)
57. Barreca ML, Ferro S, Rao A et al. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem. 48(22), 7084-7088 (2005 (Pubitemid 41533131)
58. Barreca ML, De Luca L, Iraci N et al. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J. Chem. Inf. Model. 47(2), 557-562 (2007 (Pubitemid 46615957)
59. Lin SK. Pharmacophore Perception, Development and Use in Drug Design. Güner OF (Ed.International University Line, La Jolla, CA, USA (2000
60. Wermuth G, Ganellin CR, Lindberg P, Mitscher LA. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998Pure Appl. Chem. 70(5), 1129-1143 (1998
61. Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nat. Struct. Biol. 9(9), 646-652 (2002 (Pubitemid 34977295)
62. Beaulieu PL. The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics. Idrugs 9(1), 39-43 (2006 (Pubitemid 43125541)
63. Beaulieu PL. Finger loop inhibitors of the HCV NS5B polymerase: discovery and prospects for new HCV therapy. Curr. Opin. Drug Discov. Devel. 9(5), 618-626 (2006 (Pubitemid 44378830)
64. Patel PD, Patel MR, Kaushik-Basu N, Talele TT. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors. J. Chem. Inf. Model. 48(1), 42-55 (2008 (Pubitemid 351271049)
65. Glide, version 5.7. Schrödinger, LLC, NY, USA (2011
66. Friesner RA, Banks JL, Murphy RB et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47(7), 1739-1749 (2004 (Pubitemid 38380917)
67. Friesner RA, Murphy RB, Repasky MP et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49(21), 6177-6196 (2006 (Pubitemid 44595196)
68. Halgren TA, Murphy RB, Friesner RA et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47(7), 1750-1759 (2004 (Pubitemid 38380918)
69. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 36, 3219-3228 (1980
70. Cao H, Cao R, Zhang H, Zheng X, Gao D. Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D-QSAR and molecular docking studies. Curr. Med. Chem. 15(15), 1462-1477 (2008 (Pubitemid 351997779)
71. Ewing TJA, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aid. Mol. Des. 15(5), 411-428 (2001 (Pubitemid 32452109)
72. Rong F, Chow S, Yan S, Larson G, Hong Z, Wu J. Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors. Bioorg. Med. Chem. Lett. 17(6), 1663-1666 (2007 (Pubitemid 46274352)
73. Beaulieu PL, Bos M, Bousquet Y et al. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett. 14(4), 967-971 (2004 (Pubitemid 38167623)
74. LaPlante SR, Gillard JR, Jakalian A et al. Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B. J. Am. Chem. Soc. 132(43), 15204-15212 (2010
75. Popovici-Muller J, Shipps GW, Rosner KE et al. Pyrazolo[1,5-a]pyrimidine- based inhibitors of HCV polymerase. Bioorg. Med. Chem. Lett. 19(22), 6331-6336 (2009
76. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49(2), 534-553 (2006 (Pubitemid 43157487)
77. Deng Y, Shipps GW Jr, Wang T et al. Discovery of 4H-pyrazolo[1,5-a] pyrimidin-7- ones as potent inhibitors of hepatitis C virus polymerase. Bioorg. Med. Chem. Lett. 19(18), 5363-5367 (2009
78. Talele TT, Arora P, Kulkarni SS et al. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. 18(13), 4630-4638 (2010
79. Beaulieu PL. Finger loop inhibitors of the HCVNS5B polymerase: discovery and prospects for new HCV therapy. Curr. Opin. Drug Discov. Devel. 9(5), 618-626 (2006 (Pubitemid 44378830)
80. LaPlante SR, Jakalian A, Aubry N et al. Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy. Angew. Chem. Int. Edit. 43(33), 4306-4311 (2004 (Pubitemid 39257407)
81. Kaushik-Basu N, Bopda-Waffo A, Talele TT et al. Identification and characterization of coumestans as novel HCVNS5B polymerase inhibitors. Nucleic Acids Res. 36(5), 1482-1496 (2008 (Pubitemid 351426102)
82. Jorgensen WL, Maxwell DS, TiradoRives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118(45), 11225-11236 (1996 (Pubitemid 26399746)
83. Still WC, Tempczyk A, Hawley RC, Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 112(16), 6127-6129 (1990
84. Lei BL, Du J, Li SY, Liu HX, Ren YY, Yao XJ. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors. J. Comput. Aid. Mol. Des. 22(10), 711-725 (2008
85. Singh S. Comparative QSAR Studies on the novel series of thiazolones and tetrazole derivatives as HCV NS5B polymerase allosteric inhibitors. Lett. Drug Des. Disc. 6(4), 286-297 (2009
86. Kaushik-Basu N, Bopda-Waffo A, Talele TT, Basu A, Chen Y, Kucukguzel SG. 4-thiazolidinones: a novel class of hepatitis C virus NS5B polymerase inhibitors. Front. Biosci. 13, 3857-3868 (2008 (Pubitemid 351594665)
87. Betzi S, Eydoux C, Bussetta C et al. Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step. Antivir. Res. 84(1), 48-59 (2009
88. Bohm HJ. The development of a simple empirical scoring function to estimate the binding constant for a protein ligand complex of known 3-dimensional structure. J. Comput. Aid. Mol. Des. 8(3), 243-256 (1994
89. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261(3), 470-489 (1996 (Pubitemid 26335901)
90. Kramer B, Rarey M, Lengauer T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37(2), 228-241 (1999 (Pubitemid 29503004)
91. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput. Aid. Mol. Des.10(4), 293-304 (1996 (Pubitemid 126712824)
92. Betzi S, Suhre K, Chetrit B, Guerlesquin F, Morelli X. GFscore: a general nonlinear consensus scoring function for high-throughput docking. J. Chem. Inf. Model. 46(4), 1704-1712 (2006 (Pubitemid 44185695)
93. Yan S, Appleby T, Larson G et al. Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. Bioorg. Med. Chem. Lett. 16(22), 5888-5891 (2006 (Pubitemid 44486727)
94. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267(3), 727-748 (1997 (Pubitemid 27170693)
95. Yan S, Larson G, Wu JZ et al. Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: further designs, SAR, and X-ray complex structure. Bioorg. Med. Chem. Lett. 17(1), 63-67 (2007 (Pubitemid 44959988)
96. Yan S, Appleby T, Larson G et al. Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-ray crystallographic study. Bioorg. Med. Chem. Lett. 17(7), 1991-1995 (2007 (Pubitemid 46367660)
97. Love RA, Parge HE, Yu X et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77(13), 7575-7581 (2003 (Pubitemid 36734527)
98. Chan L, Pereira O, Reddy TJ et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCVNS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides. Bioorg. Med. Chem. Lett. 14(3), 797-800 (2004 (Pubitemid 38114874)
99. Yang H, Hendricks RT, Arora N et al. Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors. Bioorg. Med. Chem. Lett. 20(15), 4614-4619 (2010
100. Maestro, version 8.5. Schrödinger LLC, NY, USA (2009
101. Louise-May S, Yang W, Nie X et al. Discovery of novel dialkyl substituted thiophene inhibitors of HCV by in silico screening of the NS5B RdRp. Bioorg. Med. Chem. Lett. 17(14), 3905-3909 (2007 (Pubitemid 46920942)
102. Lee JC, Tseng CK, Chen KJ, Huang KJ, Lin CK, Lin YT. A cell-based reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA polymerase. Anal. Biochem. 403(1-2), 52-62 (2010
103. DS LigandFit , Accelrys Software Inc., San Diego, CA, USA.
104. Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model. 21(4), 289-307 (2003 (Pubitemid 35441326)
105. Warren GL, Andrews CW, Capelli AM et al. A critical assessment of docking programs and scoring functions. J. Med. Chem. 49(20), 5912-5931 (2006 (Pubitemid 44484938)
106. Corbeil CR, Englebienne P, Yannopoulos CG et al. Docking ligands into flexible and solvated macromolecules. 2. Development and application of FITTED 1.5 to the virtual screening of potential HCV polymerase inhibitors. J. Chem. Inf. Model. 48(4), 902-909 (2008 (Pubitemid 351757755)
107. Corbeil CR, Moitessier N. Docking ligands into flexible and solvated macromolecules. 3. Impact of input ligand conformation, protein flexibility, and water molecules on the accuracy of docking programs. J. Chem. Inf. Model. 49(4), 997-1009 (2009
108. Musmuca I, Caroli A, Mai A, Kaushik-Basu N, Arora P, Ragno R. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. J. Chem. Inf. Model. 50(4), 662-676 (2010
109. Morris GM, Huey R, Lindstrom W et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30(16), 2785-2791 (2009
110. Jain AN. Ligand-based structural hypotheses for virtual screening. J. Med. Chem. 47(4), 947-961 (2004 (Pubitemid 38176797)
111. Hendricks RT, Fell JB, Blake JF et al. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors. Bioorg. Med. Chem. Lett. 19(13), 3637-3641 (2009
112. Hendricks RT, Spencer SR, Blake JF et al. 3-hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymerase. Bioorg. Med. Chem. Lett. 19(2), 410-414 (2009
113. Schmidt MW, Baldridge KK, Boatz JA et al. General atomic and molecular electronic-structure system. J. Comput. Chem. 14(11), 1347-1363 (1993
114. Melagraki G, Afantitis A, Sarimveis H, Koutentis PA, Markopoulos J, Igglessi- Markopoulou O. Identification of a series of novel derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure. Bioorg. Med. Chem. 15(23), 7237-7247 (2007 (Pubitemid 47539153)
115. Kennard RW, Stone L. Computer aided design of experiments. Technometrics 11, 137-148 (1969
116. Pourbasheer E, Riahi S, Ganjali MR, Norouzi P. QSAR study of C allosteric binding site of HCV NS5B polymerase inhibitors by support vector machine. Mol. Div. DOI 10.1007/ s11030-010-9283-9280 (2010) (Epub ahead of print
117. Chen KX, Xie HY, Li ZG. QSAR analysis of 1,1-dioxoisothiazole and benzo[b]thiophene- 1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase. Acta Chim. Slov. 56(3), 684-693 (2009
118. Chen KX, Xie HY, Li ZG. 2D-QSAR studies on anthranilic acid derivatives: a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. Chin. J. Struct. Chem. 28(10), 1217-1225 (2009
119. Parks JM, Kondru RK, Hu H, Beratan DN, Yang WT. Hepatitis C virus NS5B polymerase: QM/MM calculations show the important role of the internal energy in ligand binding. J Phys. Chem. B. 112(10), 3168-3176 (2008
120. Hu H, Yang WT. Dual-topology/dual-coordinate free-energy simulation using QM/ MM force field. J. Chem. Phys. 123(4), 041102 (2005
121. Hu H, Elstner M, Hermans J. Comparison of a QM/MM force field and molecular mechanics force fields in simulations of alanine and glycine "dipeptides" (Ace-Ala- Nme and Ace-Gly-Nme) in water in relation to the problem of modeling the unfolded peptide backbone in solution. Proteins 50(3), 451-463 (2003 (Pubitemid 36158458)
122. Frisch MJ, Schlegel HB, Scuseria GE et al. Gaussian 03, Revision C.02. Gaussian Inc., Wallingford, CT, USA (2004
123. Chen Y, Bopda-Waffo A, Basu A et al. Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor. Antivir. Chem. Chemother. 20(1), 19-36 (2009
124. Ruebsam F, Murphy DE, Tran CV et al. Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett. 19(22), 6404-6412 (2009
125. de Vicente J, Hendricks RT, Smith DB et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids. Bioor. Med. Chem. Lett. 19(19), 5648-5651 (2009
126. de Vicente J, Hendricks RT, Smith DB et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides. Bioorg. Med. Chem. Lett. 19(19), 5652-5656 (2009
127. Vandyck K, Cummings MD, Nyanguile O et al. Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase. J. Med. Chem. 52(14), 4099-4102 (2009
128. Mohamadi F, Richards NGJ, Guida WC et al. Macromodel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11(4), 440-467 (1990
129. Nyanguile O, Devogelaere B, Vijgen L et al. 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus. J. Virol. 84(6), 2923-2934 (2010
130. Bressanelli S, Tomei L, Roussel A et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA 96(23), 13034-13039 (1999
131. Ryu K, Kim ND, Choi SI et al. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorg. Med. Chem. 17(8), 2975-2982 (2009
132. Li T, Froeyen M, Herdewijn P. Insight into ligand selectivity in HCV NS5B polymerase: molecular dynamics simulations, free energy decomposition and docking. J. Mol. Model. 16(1), 49-59 (2009
133. Wang X, Yang W, Xu X, Zhang H, Li Y, Wang Y. Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. Curr. Med. Chem. 17(25), 2788-2803 (2010
134. Le Pogam S, Seshaadri A, Kosaka A et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61(6), 1205-1216 (2008 (Pubitemid 351753583)
135. Chen CM, He Y, Lu L et al. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob. Agents Chemother. 51(12), 4290-4296 (2007 (Pubitemid 350209879)
136. Patil VM, Gupta SP, Samanta S, Neeraj M. 3D-QSAR Knn MFA study on thiouracil derivatives as hepatitis C virus inhibitors. Med. Chem. Res. 19, S98 (2010
137. Das K, Bauman JD, Clark AD Jr et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. USA 105(5), 1466-1471 (2008 (Pubitemid 351346537)
138. PyMOL Molecular Graphics System, version 1.2r3pre. Schrödinger, LLC, NY, USA.
139. ACD/ChemSketch, version 12.00. Advanced Chemistry Development, Inc, Toronto, ON, Canada (2010).